Calamos Advisors’s Haemonetics HAE Stock Holding History

Calamos Advisors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,600	Closed	-$360K	–	673
2018 Q4	$360K	Hold	3,600	–	–	﹤0.01%	607
2018 Q3	$412K	Buy	+3,600	New	+$373K	﹤0.01%	611

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Calamos Advisors's HAE Position: Q1 2019 in Review

Calamos Advisors sold out of Haemonetics (HAE) in Q1 2019, closing a stake of 3,600 shares — an estimated $360K sold.

Calamos Advisors first reported a position in HAE in Q3 2018 and held it in 2 quarters. The position peaked at $412K in Q3 2018. 260 funds tracked by Wall St. Rank hold HAE as of Q1 2019.

Calamos Advisors reported no remaining Haemonetics position as of Q1 2019 after selling out during the quarter.
Calamos Advisors sold 3,600 Haemonetics shares in Q1 2019, an estimated $360K.
Calamos Advisors first reported a position in Haemonetics in Q3 2018 and held it in 2 quarters.
Calamos Advisors's Haemonetics position peaked at $412K in Q3 2018.
260 funds tracked by Wall St. Rank held Haemonetics as of Q1 2019.

Based on Calamos Advisors's 13F filing for Q1 2019, filed 12 Apr 2019.